amifampridine used drug predominantly treatment number rare muscle diseases free base form drug used treat congenital myasthenic syndromes myasthenic syndrome lems compassionate use programs since recommended first line treatment lems using ad hoc forms drug since marketed form around doctors assistance publique hôpitaux de paris created phosphate salt form developed series companies ending biomarin pharmaceutical obtained european approval trade name firdapse licensed us rights catalyst pharmaceuticals january catalyst another us company jacobus pharmaceutical manufacturing giving away free since seeking fda approval iterations marketing rights amifampridine phosphate orphan drug status eu myasthenic syndrome catalyst holds orphan designation breakthrough therapy designation us may us food drug administration fda approved amifampridine tablets trade name ruzurgi treatment lamberteaton myasthenic syndrome lems patients less years age first fda approval treatment specifically pediatric patients lems fda granted approval ruzurgi jacobus pharmaceutical treatment approved lems firdapse approved use amifampridine used treat many congenital myasthenic syndromes particularly defects choline acetyltransferase downstream kinase kind defect causes fast channel behaviour acetylcholine also used treat symptoms myasthenic affects voltagegated ion channels heart contraindicated people long qt syndrome people taking drug might prolong qt time like sultopride disopyramide cisapride domperidone rifampicin ketoconazol also contraindicated people epilepsy badly controlled doselimiting side effects include tingling numbness difficulty sleeping fatigue loss muscle amifampridine cause seizures especially exclusively given high doses andor particularly vulnerable individuals history combination amifampridine pharmaceuticals prolong qt time increases risk ventricular tachycardia especially torsade de pointes combination drugs lower seizure threshold increases risk seizures interactions via livers cytochrome enzyme system considered myasthenic syndrome acetylcholine release inhibited antibodies involved host response certain cancers crossreact channels prejunctional membrane amifampridine works blocking potassium channel efflux nerve terminals action potential duration channels open longer time allow greater acetylcholine release stimulate muscle end amifampridine quickly almost completely absorbed gut study healthy subjects maximum amifampridine concentrations blood plasma reached hours taken without food hours fatty meal meaning speed absorption varies widely biological halflife hrs area curve auc also vary widely subjects nearly independent food substance deactivated acetylation via nacetyltransferases single metabolite activity enzymes primarily nacetyltransferase different individuals seems primarily responsible mentioned differences halflife auc latter increased slow metabolizers compared fast amifampridine eliminated via kidneys urine nacetylamifampridine unchanged pale yellow pale brown crystalline powder melts decomposition readily soluble methanol ethanol hot water slightly diethyl solubility water gl drug formulation amifampridine phosphate contains phosphate salt specifically dihydrogen salt forms prismatic monoclinic crystals space group readily soluble phosphate salt stable require development amifampridine phosphate brought attention orphan drug policies grant market exclusivity incentive companies develop therapies conditions affect small numbers amifampridine also called discovered scotland doctors sweden first showed use lems doctors us behalf muscular dystrophy association approached small familyowned manufacturer active pharmaceutical ingredients new jersey jacobus pharmaceuticals manufacturing amifampridine could test clinical trials jacobus treatment turned effective jacobus doctors faced choice invest clinical trials get fda approval give drug away free compassionate use program patients estimated lems patients us jacobus elected give drug away subset lems patients twenty doctors assistance publique hôpitaux de paris created phosphate salt obtained orphan designation europe hospital licensed intellectual property phosphate form french biopharma company opi acquired eusa pharma orphan application transferred eusa eusa submitted application approval market phosphate form european medicines agency brand name eusa vehicle called huxley pharmaceuticals sold rights biomarin year approved europe new name licensing firdapse europe led sharp increase price drug cases led hospitals using unlicensed form rather licensed agent price difference proved prohibitive biomarin criticized licensing drug basis previously conducted research yet charging exorbitantly group uk neurologists pediatricians petitioned prime minister david cameron open letter review company responded submitted licensing request suggestion french government points increased cost licensed drug also means monitored regulatory authorities eg uncommon side effects process previously present cochrane review compared cost uk found average price base average price phosphate authors estimated yearly cost per person base versus phosphate meanwhile europe task force neurologists recommended firstline treatment lems symptoms even though approved form marketing supplied ad drugs international nonproprietary name published face sevenyear exclusivity orphan approval would give biomarin increase price would accompany jacobus began racing conduct formal clinical trials order get approval free base form biomarin first phase ii trial opened january october biomarin phase iii trial ongoing us licensed us rights including orphan designation ongoing trial catalyst catalyst anticipated could earn million per year sales peak sales treatment people lems indications analysts anticipated drug would priced around catalyst went obtain breakthrough therapy designation lems orphan designation congenital myasthenic syndromes orphan designation myasthenia gravis august analysts anticipated fda approval would granted catalyst lems october catalyst began making available expanded access march catalyst obtained orphan designation use treat congenital myasthenic april jacobus presented clinical trial results scientific december group neuromuscular doctors worked jacobus biomarincatalyst published editorial journal muscle nerve expressing concern potential price drug dramatically increased catalyst obtain fda approval stating represented real innovation didnt deserve exclusivity orphan drug act meant spur innovation meet unmet catalyst responded editorial response explained catalyst conducting full range clinical nonclinical studies necessary obtain approval order specifically address unmet need among estimated lems patients since receiving product compassionate use exactly orphan drug act intended deliver approved products orphan drug populations patients full december catalyst submitted new drug application february fda refused accept basis wasnt complete april fda told catalyst would gather catalyst cut workforce mainly commercial team building support approved product save money conduct march company resubmitted fda approved amifampridine treatment adults lamberteaton myasthenic syndrome november february us senator bernie sanders questioned high price charged catalyst pharmaceuticals may privately held us company jacobus pharmaceutical princeton new jersey gained approval fda amifampridine tablets ruzurgi treatment lems patients less years age first fda approval treatment specifically pediatric patients lems firdapse approved use although ruzurgi approved pediatric patients approval makes possible adults lems get drug offlabel jacobus pharmaceutical manufacturing giving away free since fda decision dropped stock catalyst pharmaceuticals companys stock price dropped amifampridine also proposed treatment multiple sclerosis ms cochrane systematic review found unbiased data support use treating change httpsenwikipediaorgwikiamifampridine